Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

short term income and recurring revenue streams from a successful product launch in the future.

Regulatory strategy

CeNeS preferred strategy is for a partner to be involved in the key decisions regarding regulatory filing strategies both in Europe and in United States. The strategy in the USA is clear. The strong data obtained from the most recent Phase III study validates the proposed product profile of M6G and strengthens CeNeS position with potential North American partners. Registration could be achieved in the USA in 2009 after conducting two Phase III studies to the requirements of the FDA. It is important to note that the quality and robustness of the clinical data produced by the current study significantly reduces the risk for the development of M6G by enabling optimal trial design and the selection of endpoints in the remaining Phase III studies.

In Europe the narrow failure to achieve statistical significance with the second chosen primary endpoint of incidence and severity of nausea (p=0.052 not p<0.050) offers three options:

1) Pursue a filing application in certain European countries with the comprehensive clinical data package that CeNeS has assembled. 2) Further strengthen the European package by conducting an additional European Phase III study which would complete in 2008 with product filing in 2009. 3) Use the USA Phase III trials to support the European application, potentially with a global partner.

CeNeS will continue to discuss the above strategies with regulatory consultants and potential partners.

Neil Clark, Chief Executive of CeNeS commented "The ongoing analysis of the Phase III results further confirms our belief in the excellent potential of M6G as a novel product for post- operative pain. The quality and breadth of the data contained in this large study supports M6G's anticipated product profile.

The potential for reduced anti-emetic drug costs combined with the reduction in medical assi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
(Date:7/31/2014)... SUNNYVALE, Calif. , July 31, 2014  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Management Access Conference, New York, NY ... Baird Health Care Conference, New York, ... Eastern Time , Accessing Live Webcasts To access ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2
... Technologies, Inc. (Nasdaq: NTII ) and the ... have entered into a,collaboration and exclusive license agreement ... Under the terms of the agreement,Neurobiological Technologies will ... occurring protein that has been shown in animals ...
... Patient ... Population -, ... Bristol-Myers Squibb Company (NYSE: BMY ),announced today that the U.S. ... ABILIFY(R) (aripiprazole) for the,acute treatment of manic and mixed episodes associated ...
Cached Medicine Technology:Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease 2Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 2U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 4U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 5U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 6U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 7U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 8U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) 9
(Date:7/31/2014)... A program for anyone looking to experience weight ... of Colorado Anschutz Health and Wellness Center (AHWC) ... transformation program. , “Extreme Weight Loss: Destination Boot ... an evidenced-based program inspired by the unscripted series “Extreme ... season, the show has participants spending their first three ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... closure in front of an enthusiastic audience of international ... Trichophytic Closure improves the appearance of a patient’s ... results of this procedure are minimally detectable in most ... technique improves on the original method of donor wound ...
(Date:7/31/2014)... You’re having a wonderful summer—sunning, gardening, enjoying BBQs ... chills and fever, headache, stiff neck, achey joints, and a ... it could actually be the first sign of Lyme ... is greater than you might think. Until last year, it ... U.S. annually. But the Centers for Disease Control and Prevention ...
(Date:7/31/2014)... San Diego, CA (PRWEB) July 31, 2014 ... by the Philadelphia Business Journal , Endo International, one ... agreed to settle thousands of transvaginal claims for $830 ... Systems Products Liability Litigation (MDL No. 2325). Melinda Helbock, ... A.P.C., said she agrees with the settlement and is ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces ... is simplified and predictable with fixed fees across the ... leading international provider of legal discovery management services for ... glaringly apparent that both the courts and legal counsel ... the complex pricing structure that plagues the litigation support ...
Breaking Medicine News(10 mins):Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3Health News:Novel Technique in Wound Closure Delivers More Discreet Results in Hair Transplant Patients 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3Health News:San Diego Product Liability Firm Provides Commentary on the Latest Developments in Transvaginal Mesh Litigation 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2
... Phoebe Prince was stalked ... staple of youth culture. Keith Deltano is using comedy to fight this serious problem., ... (PRWEB) May 24, 2010 -- Phoebe Prince ... where students are being bullied to death, is comedy the appropriate vehicle to use to address ...
... ... Food & Drug Administration’s Center for Drug Evaluation and Research (CDER) will soon ... including “SPF,” “anti-aging,” or “anti-wrinkle,” according to Benjamin L. England, former 17-year FDA ... ...
... Company ... ... Corporation announced it has joined the American Academy of Healthcare Interior Designers (AAHID) as ... the knowledge, skills and abilities of healthcare interior designers. Board Certified Healthcare Interior Design ...
... ... been named by the United States Public Health Service Commissioned Officers Association as the 2010 ... individuals who have provided significant leadership to the advancement of the health of the American ... ...
... ... Breaks , ... -- A lawsuit has been filed in the Federal District Court of the United States for ... of current and former CVS employees alleging violations of the Fair Labor Standards Act and New ...
... ... 501(c)(3) application is filed, it has a bank account, and it even has a ... What it needs now is a logo, and it has launched a nationwide contest ... Spice House, singer Gretchen Wilson, and writer Michael Z. Williamson. , ...
Cached Medicine News:Health News:Bullying Assembly Uses Comedy to Reach Students 2Health News:Bullying Assembly Uses Comedy to Reach Students 3Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal &#8220;Anti-Aging&#8221; Labeling Claims, According to FDAImports.com, LLC 2Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal &#8220;Anti-Aging&#8221; Labeling Claims, According to FDAImports.com, LLC 3Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal &#8220;Anti-Aging&#8221; Labeling Claims, According to FDAImports.com, LLC 4Health News:InPro Becomes AAHID Industry Partner 2Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 2Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 3Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 4Health News:National Employee Collective and Class Action Lawsuit Filed Against CVS 2Health News:Art Contest for New Charity With A History 2Health News:Art Contest for New Charity With A History 3Health News:Art Contest for New Charity With A History 4
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
... iMRI is a neurosurgical OR that ... diagnostic tools, including iMRI, necessary to ... iMRI, neurosurgical treatments are performed in ... designed for MR compatibility and safety, ...
... Compact is the first magnetic stimulator to ... magnetic stimulation. It is designed to provide ... the diagnostic routine (at the same time, ... since you can control operations without moving ...
... X-SIZER System is a ... for thrombus removal in ... saphenous vein grafts. ... cutter and,continuous evacuation. ...
Medicine Products: